Will your breakfast ruin this cancer pill? new trial investigates
NCT ID NCT07550946
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial in 24 healthy adults examines how food and a common stomach-acid reducer (a proton pump inhibitor) change the way the body absorbs a new drug called VRN101099, which is being developed for solid tumors. Researchers will measure drug levels in the blood and urine under different conditions to find the best way to take it. The goal is to guide future dosing instructions for cancer patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VRN101099
What this could lead to
If successful, this study will help determine the best way to take VRN101099 with or without food or acid reducers, potentially improving future cancer treatments.
What could go wrong
This is an early phase 1 trial in only 24 healthy people, not patients. Results may not predict effects in cancer patients or guarantee safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact